Vetoquinol S.A. (VETO.PA)
Vetoquinol S.A. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lure, BF, FR. The stock last traded at $71.40, down 0.56% on the session, giving a market capitalisation of $830.0M. Its beta of 0.88 implies it has historically moved less than the broad market.
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
Vetoquinol S.A. is most often compared with the following Healthcare names: